Table 3

Clinical characteristics of 75 ACA+ (>74

Variable

Anti-FOXE3p53-62

P-value


Positive (n = 40)

Negative (n = 35)


Female, n (%)

38 (95.0)

33 (94.3)

1.000a

Age at diagnosis, years

37.4 (14.2)

41.5 (13.0)

0.217b

Disease duration, years

20.3 (11.9)

16.2 (8.5)

0.151b

Disease subtype, limited, n (%)

37 (92.5)

33 (94.3)

0.757a

Anti-Ap1-17 IgG, µg/ml

252.50 (954.00)

161.00 (313.00)

0.807b

Anti-Ap17-30 IgG, µg/ml

9.63 (7.00)

5.23 (7.20)

<0.0001b

mRss

3.70 (4.20)

4.10 (8.40)

0.533b

FVC, % of predicted

110.6 (17.0)

103.7 (20.6)

0.201b

DLCO, % of predicted

76.2 (24.0)

76.6 (24.6)

0.727b

sPAP, mm Hg

29.00 (14.20)

26.20 (8.20)

0.510b

ILD, n (%)

8 (20.0)

5 (15.2)

0.590 a

PAH, n (%)

5 (12.5)

3 (8.6)

0.719a

Disease severity score

5.30 (2.70)

5.00 (2.30)

0.570b

Disease activity index

0.91 (0.91)

1.61 (1.61)

0.038b

Disease activity index domains

mRss >14 (0.0, 1.0)

0.02 (0.16)

0.03 (0.17)

0.980

Scleredema (0.0, 0.5)

0.11 (0.21)

0.11 (0.21)

0.971

Skin (0.0, 2.0)

0.05 (0.30)

0.10 (0.50)

0.481

Digital necrosis (0.0, 0.5)

0.07 (0.18)

0.04 (0.14)

0.396

Vascular (0.0, 0.5)

0.06 (0.16)

0.06 (0.16)

0.887

Arthritis (0.0, 0.5)

0.07 (0.20)

0.06 (0.16)

0.652

DLCO <80% of predicted (0.0, 0.5)

0.26 (0.25)

0.20 (0.25)

0.282

Heart/lung function (0.0, 2.0)

0.05 (0.31)

0.40 (0.81)

0.015

ESR >30 mm/h (0.0, 1.5)

0.18 (0.50)

0.30 (0.60)

0.380

Low C3 or C4 (0.0, 1.0)

0.05 (0.22)

0.31 (0.50)

0.003


Values are presented as mean (SD) unless otherwise indicated. aChi-squared test; bMann-Whitney U-test; a P-value <0.05 was considered significant. SSc, systemic sclerosis; ACA, anti-centromere-associated protein antibodies; mRss, modified Rodnan skin score; FVC, forced vital capacity; DLCO, diffusing lung capacity for carbon monoxide; sPAP, systolic pulmonary arterial pressure; ILD, interstitial lung disease assessed by high resolution computed tomography; PAH, pulmonary arterial hypertension (sPAP >35 mm Hg); ESR, erythrocyte sedimentation rate in the first hour. Cardiac involvement was evaluated by electrocardiography, echocardiography and physical examination.

Perosa et al. Arthritis Research & Therapy 2013 15:R72   doi:10.1186/ar4249

Open Data